Literature DB >> 11177728

Influence of Pharmacokinetic and Pharmacodynamic Principles on Antibiotic Selection.

George G. Zhanel1.   

Abstract

When evaluating the efficacy of antibiotics for the treatment of respiratory tract infections, such as community acquired pneumonia and acute exacerbations of chronic bronchitis, assessment of clinical cure may not be the most relevant parameter, as it may not be related to microbiological eradication or to the minimum inhibitory concentration (MIC) of the infecting pathogen. It is more relevant to study the efficacy of the antibiotic in eradicating the bacterial pathogen, because this is frequently related to both the MIC of the pathogen and the antibiotic dosage regimen. Pharmacodynamics correlates the concentration of antibiotic in the blood or at the infection site with its biological effect against the organism (bacteriological eradication). For beta-lactams, the pharmacodynamic parameter that best correlates with eradication is time (T) above MIC (T > MIC); for aminoglycosides and fluoroquinolones, it is the area under the curve at 24 hours (AUC(24))-to-MIC ratio (AUC(24)/MIC). Knowledge of pharmacodynamics allows optimum use of antibiotics; in vitro models, animal models, and retrospective and prospective clinical trials have shown that the use of such knowledge optimizes bacteriological eradication and enhances patient outcome. In the future, pharmacodynamic studies will be used not only to assess optimal ways for antibiotics to eradicate resistant pathogens, but also to investigate the ability of antibiotics to prevent the development of resistance on therapy and to eradicate pathogens from colonizing sites.

Entities:  

Year:  2001        PMID: 11177728     DOI: 10.1007/s11908-001-0056-x

Source DB:  PubMed          Journal:  Curr Infect Dis Rep        ISSN: 1523-3847            Impact factor:   3.725


  32 in total

Review 1.  Evolving patterns of resistance to respiratory pathogens in Canada.

Authors:  D J Hoban; J A Karlowsky; G G Zhanel
Journal:  Can Respir J       Date:  1999 Jan-Feb       Impact factor: 2.409

Review 2.  Pharmacodynamics to combat resistance.

Authors:  G Woodnutt
Journal:  J Antimicrob Chemother       Date:  2000-07       Impact factor: 5.790

3.  Prevalence of antimicrobial resistance among respiratory tract isolates of Streptococcus pneumoniae in North America: 1997 results from the SENTRY antimicrobial surveillance program.

Authors:  G V Doern; M A Pfaller; K Kugler; J Freeman; R N Jones
Journal:  Clin Infect Dis       Date:  1998-10       Impact factor: 9.079

4.  Pharmacokinetics and pharmacodynamics of oral grepafloxacin in patients with acute bacterial exacerbations of chronic bronchitis.

Authors:  A Forrest; S Chodosh; M A Amantea; D A Collins; J J Schentag
Journal:  J Antimicrob Chemother       Date:  1997-12       Impact factor: 5.790

5.  Pharmacodynamics of levofloxacin and ciprofloxacin against Streptococcus pneumoniae.

Authors:  P D Lister; C C Sanders
Journal:  J Antimicrob Chemother       Date:  1999-01       Impact factor: 5.790

Review 6.  Pharmacokinetics and pharmacodynamics of fluoroquinolones.

Authors:  J Turnidge
Journal:  Drugs       Date:  1999       Impact factor: 9.546

7.  A multicentre collaborative study of the antimicrobial susceptibility of community-acquired, lower respiratory tract pathogens 1992-1993: the Alexander Project.

Authors:  D Felmingham; R N Grüneberg
Journal:  J Antimicrob Chemother       Date:  1996-07       Impact factor: 5.790

Review 8.  Acute otitis media: management and surveillance in an era of pneumococcal resistance--a report from the Drug-resistant Streptococcus pneumoniae Therapeutic Working Group.

Authors:  S F Dowell; J C Butler; G S Giebink; M R Jacobs; D Jernigan; D M Musher; A Rakowsky; B Schwartz
Journal:  Pediatr Infect Dis J       Date:  1999-01       Impact factor: 2.129

Review 9.  The importance of pharmacokinetic/pharmacodynamic surrogate markers to outcome. Focus on antibacterial agents.

Authors:  J M Hyatt; P S McKinnon; G S Zimmer; J J Schentag
Journal:  Clin Pharmacokinet       Date:  1995-02       Impact factor: 6.447

10.  Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients.

Authors:  A Forrest; D E Nix; C H Ballow; T F Goss; M C Birmingham; J J Schentag
Journal:  Antimicrob Agents Chemother       Date:  1993-05       Impact factor: 5.191

View more
  5 in total

1.  Population pharmacokinetic and pharmacodynamic modeling of norvancomycin.

Authors:  J Zhang; Y Zhang; Y Shi; J Rui; J Yu; G Cao; J Wu
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2008-01-09       Impact factor: 3.267

2.  Pharmacodynamic activity of telithromycin at simulated clinically achievable free-drug concentrations in serum and epithelial lining fluid against efflux (mefE)-producing macrolide-resistant Streptococcus pneumoniae for which telithromycin MICs vary.

Authors:  George G Zhanel; Christel Johanson; Nancy Laing; Tamiko Hisanaga; Aleksandra Wierzbowski; Daryl J Hoban
Journal:  Antimicrob Agents Chemother       Date:  2005-05       Impact factor: 5.191

Review 3.  New developments in antibacterial choice for lower respiratory tract infections in elderly patients.

Authors:  Anna Maria Ferrara; Anna Maria Fietta
Journal:  Drugs Aging       Date:  2004       Impact factor: 3.923

Review 4.  The ketolides: a critical review.

Authors:  George G Zhanel; Michael Walters; Ayman Noreddin; Lavern M Vercaigne; Aleksandra Wierzbowski; John M Embil; Alfred S Gin; Stephen Douthwaite; Daryl J Hoban
Journal:  Drugs       Date:  2002       Impact factor: 9.546

5.  Pharmacokinetics of sarafloxacin in allogynogenetic silver crucian carp, Carassius auratus gibelio.

Authors:  Xingxing Fang; Jianguo Zhou; Xiuhong Liu
Journal:  Fish Physiol Biochem       Date:  2015-11-12       Impact factor: 2.794

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.